Curated News:

NEJM

Add to Favorites | Subscribe | Share

Filters:

  • (Press "esc" to clear)

Medicine

Channels:

ventricular tachycardia, Radiation Therapy

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 13-Dec-2017 5:00 PM EST

Medicine

Channels:

Phase 2 CAR-T Study Reports Significant Remission Rates at 15-Month Follow Up

Neelapu.jpg

A study involving the recently approved CD19-targeting chimeric antigen receptor (CAR) T cell therapy shows that 42 percent of patients with aggressive large B-cell lymphoma remained in remission at 15 months following treatment with axi-cel (marketed as Yescarta™).

Medicine

Channels:

CAR-T cell therapy, Lymphoma

Landmark CAR-T Cancer Study Published in the New England Journal of Medicine

CAR-TInfographic.jpg

Loyola University Medical Center is the only Chicago center that participated in the pivotal clinical trial of a groundbreaking cancer treatment that genetically engineers a patient's immune system to attack cancer cells.

Medicine

Channels:

Deep Vein Thrombosis, ATTRACT trial, post-thrombotic syndrome, Blood Clot

Clot-Busting Drugs Not Recommended for Most Patients with Blood Clots

About half of people with blood clots in the deep veins of their legs develop a complication that involves chronic limb pain and swelling, making it difficult to walk and perform daily activities. A large-scale clinical trial has shown that a risky, costly procedure to remove such clot fails to reduce the likelihood that patients will develop the debilitating complication.

Medicine

Channels:

Hematology, Gene Therapy, Clinical Trial, Hemophilia B, clotting factor, Fix, Genetic Disease

One-Dose Gene Therapy Produces Clotting Factor, Safely Stops Bleeding in Hemophilia B Patients

GeorgeLindseyRGB-16.jpg

A team of gene therapy researchers has reported positive results in a phase 1/2 clinical trial for the inherited bleeding disorder hemophilia B. A single intravenous infusion of a novel bioengineered gene therapy treatment enabled adult participants to safely produce sustained levels of clotting factor that prevented debilitating bleeding episodes. Patients were able to terminate prophylactic treatments--the gene therapy nearly universally eliminated their need for intravenous infusions of manufactured clotting factor.

Medicine

Channels:

Spark Therapeutics and Pfizer Announce Publication in The New England Journal of Medicine of Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Hemophilia B

Spark Therapeutics (NASDAQ: ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, and Pfizer Inc. (NYSE:PFE), today announced that The New England Journal of Medicine has published interim data as of July 25, 2017, from the Phase 1/2 clinical trial of SPK-9001, an investigational gene therapy for hemophilia B.

Medicine

Channels:

Immunotherapy, Migraine, Clinical Trial, phase 3, Headache

Phase III Immunotherapy Trial for Migraine Shows Positive Results

An antibody therapy against a key inflammatory molecule involved in migraines reduces the number of headaches that chronic migraine patients experience per month in a phase III trial.

Medicine

Channels:

Johns Hopkins, Charles Flexner, Charles Holmes, AIDS, HIV, Uganda, Izukanji Sikazwe , World Aids Day, Rakai, Larry Chang, Prefar, Antiretroviral, CIDRZ, Zambia

World AIDS Day: New Research and Experts Available from Johns Hopkins Medicine

WorldAidsDayiStock-622991036web.jpg

Experts from Johns Hopkins Medicine are available to talk about AIDS/HIV, and there is new research from Johns Hopkins on the topic.

Medicine

Channels:

HIV, Hiv Prevention, Pepfar

Male Circumcision and Antiviral Drugs Appear to Sharply Reduce HIV Infection Rate

A steep drop in the local incidence of new HIV infections accompanied the rollout of a U.S.-funded anti-HIV program in a large East-African population, according to a study led by researchers at Johns Hopkins Bloomberg School of Public Health and Johns Hopkins School of Medicine.

Medicine

Channels:

Stroke, Thrombectomy, Stroke Treatment, Stroke Recovery, Stroke research

Landmark DAWN Study Expands Treatment Window for Strokes

The final results of the DAWN study, published in The New England Journal of Medicine, show that select patients with stroke caused by a blood clot can be effectively treated with a procedure to remove the clot mechanically – and that this can be done up to 24 hours after the onset of symptoms.







Chat now!